SCHEMBL3017384

SCHEMBL3017384

Oc1nn(Cc2ccccc2)c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.58
ACHE P22303 1/20 0.58
CNR2 P34972 1/20 0.58
PDE5A O76074 4/20 0.52
CYP1A2 P05177 3/20 0.52
CYP2D6 P10635 3/20 0.52
KDM4E B2RXH2 2/20 0.52
CYP3A4 P08684 2/20 0.52
ALDH1A1 P00352 2/20 0.52
NPC1 O15118 1/20 0.52
GMNN O75496 1/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
MAPT P10636 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
ALOX15 P16050 1/20 0.52
NFKB1 P19838 1/20 0.52
MAPK1 P28482 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10627901 0.98 CNR1 (0.56) CNR1ACHECNR2PDE5ACYP1A2
SCHEMBL10627892 0.98 CNR1 (0.56) CNR1ACHECNR2PDE5ACYP1A2
SCHEMBL516208 0.83 CNR2 (0.66) CNR1ACHECNR2KDM4EALDH1A1
SCHEMBL30602811 0.81 PTGDR2 (0.46) CNR1ACHECNR2PDE5ACYP1A2
SCHEMBL9917435 0.81 PDE5A (0.49) CNR1ACHECNR2PDE5AKDM4E
SCHEMBL17696321 0.80 CNR1 (0.59) CNR1ACHECNR2PDE5ACYP1A2
SCHEMBL29342349 0.80 CNR1 (0.59) CNR1ACHECNR2PDE5ACYP1A2
SCHEMBL928055 0.79 SLC16A3 (0.58) CNR1ACHECNR2PDE5ACYP1A2
SCHEMBL29562418 0.79 SLC16A3 (0.58) CNR1ACHECNR2PDE5ACYP1A2
SCHEMBL1226080 0.79 CNR1 (0.58) CNR1ACHECNR2PDE5ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822396-B2 Solution for removing residue after semiconductor dry process and method of removing the residue using the same DAIKIN INDUSTRIES, LTD. (JP) 2014-09-02 US claimed
CN-102839062-A Application of residue-removing solution DAIKIN IND LTD 2012-12-26 CN claimed
US-20100203735-A1 SOLUTION FOR REMOVING RESIDUE AFTER SEMICONDUCTOR DRY PROCESS AND METHOD OF REMOVING THE RESIDUE USING THE SAME DAIKIN INDUSTRIES, LTD. (JP) 2010-08-12 US claimed
CN-101785087-A Residue removing liquid after semiconductor dry process and residue removing method using the same DAIKIN IND LTD 2010-07-21 CN claimed
US-20240216332-A1 METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING MYOPIA GRAND PHARMA (CHINA) CO., LTD. (CN) 2024-07-04 US disclosed
CN-118236372-A Medicament and method for treating myopia 温州医科大学附属眼视光医院 2024-06-25 CN disclosed
EP-4324463-A1 METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING MYOPIA Grand Pharma (China) Co., Ltd. (CN) 2024-02-21 EP disclosed
CN-110036341-B Photosensitive resin composition, photosensitive resin laminate, method for producing resin pattern, and method for producing cured film pattern 旭化成株式会社 2023-06-09 CN disclosed
CN-114609864-A Photosensitive resin composition 旭化成株式会社 2022-06-10 CN disclosed
CN-106918995-B Photosensitive resin composition, photosensitive resin laminate, method for producing resin pattern and cured film pattern, and display device 旭化成株式会社 2020-06-02 CN disclosed
WO-2019164016-A1 TRANSFER FILM, RESIN PATTERN FORMING METHOD USING TRANSFER FILM, AND CURED FILM PATTERN FORMING METHOD 旭化成株式会社 2019-08-29 WO disclosed
CN-110036341-A Photosensitive resin composition, photosensitive resin laminate, method for producing resin pattern, and method for producing cured film pattern 旭化成株式会社 2019-07-19 CN disclosed
US-20100015093-A1 Methods and compositions of treating a flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2010-01-21 US disclosed
US-20100015093-A1 Methods and compositions of treating a flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2010-01-21 US disclosed
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase ABBOTT LABORATORIES 2004-03-11 US disclosed
WO-2003076408-A2 INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ABBOTT LABORATORIES (US) 2003-09-18 WO disclosed
WO-2000027394-A1 ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE UNIVERSITY COLLEGE LONDON (GB) 2000-05-18 WO disclosed
US-5965582-A ANTIHISTAMINES ASTA MEDICA AKTIENGESELLSCHAFT (DE) 1999-10-12 US disclosed
US-5776932-A ANTIALLERGENS, ANTIASTHMATICS, ANTIINFLAMMATORY AGENTS AND MODULATORS ARZNEIMITTELWERK DRESDEN G.M.B.H. (DE) 1998-07-07 US disclosed
US-4749794-A REMOVING 1-CHLORO-3-METHYLAMINOPROPANE IMPURITY FROM CRUDE PRODUCT AZIENDE CHIMICHE RIUNUTE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 1988-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048866-A1 Indazole derivatives that are activators of soluble guanylate cyclase GUCY1B1, GUCY1A1, GUCY1A2 CNR1 1179/4885ACHE 710/4885CNR2 1561/4885
US-20100015093-A1 Methods and compositions of treating a flaviviridae family viral infection EIF2AK2, NSUN3, NSUN2 CNR1 3683/4885ACHE 3660/4885CNR2 3370/4885
US-20240216332-A1 METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING MYOPIA MYOC, PDE6H, RHOA CNR1 856/4885ACHE 235/4885CNR2 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.